Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Mehmet Asim Bilen"'
Autor:
Mehmet Asim Bilen, Jodi Lyn Layton, Whitley Hatton, Hamid Emamekhoo, Vadim S. Koshkin, Patrick Cotogno, Arpita Desai, Ellen Jaeger, Oliver Sartor, Charlotte Manogue, Pedro C. Barata, Brian E. Lewis, Arnab Basu, Deepak Kilari, Malcolm Light
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology
Frontiers in Oncology
Introduction: The treatment landscape of metastatic renal cell carcinoma has advanced significantly with the approval of combination regimens containing an immune checkpoint inhibitor (ICI) for patients with treatment-naive disease. Little informatio
Autor:
Despina Thomaidou, Marc-Oliver Grimm, Christian Kollmannsberger, Alessandra di Pietro, Mariangela Mariani, Matthew D Tucker, Bo Huang, Mehmet Asim Bilen, Paul Nathan, Yoshihiko Tomita, Martin H. Voss, Brian I. Rini, Toni K. Choueiri
Publikováno v:
Journal of Clinical Oncology. 39:4549-4549
4549 Background: Baseline NER has been reported to be associated with outcomes of immuno-oncology based combination treatment in advanced renal cell carcinoma (aRCC). We report outcomes by baseline NER of patients with aRCC in the JAVELIN Renal 101 t
Autor:
Mehmet Asim Bilen, Lauren Yantorni, Bradley Curtis Carthon, Viraj A. Master, Limeng Wan, Jacqueline T. Brown, Sarah Caulfield, Omer Kucuk, Katherine Emilie Rhoades Smith, Greta Russler, Bassel Nazha, Yuan Liu
Publikováno v:
Journal of Clinical Oncology. 39:e17049-e17049
e17049 Background: There is limited biomarker data available for metastatic hormone sensitive prostate cancer (mHSPC). Inflammatory markers found on routine clinical lab data, including leukocyte to lymphocyte ratios calculated from complete blood co
Autor:
Ragini R. Kudchadkar, Dylan J. Martini, Conor E. Steuer, R. Donald Harvey, Colleen Lewis, Viraj A. Master, Mehmet Akce, Haydn T. Kissick, Bassel F. El-Rayes, Mehmet Asim Bilen, Olatunji B. Alese, Walid L. Shaib, Bradley C. Carthon, Taofeek K. Owonikoko, Yuan Liu, David H. Lawson, Hannah Collins, Christina Wu, Julie M. Shabto, Suresh S. Ramalingam
Publikováno v:
BMC Cancer
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
Background Selecting the appropriate patients to receive immunotherapy (IO) remains a challenge due to the lack of optimal biomarkers. The presence of liver metastases has been implicated as a poor prognostic factor in patients with metastatic cancer
Autor:
Reza Nabavizadeh, Mehmet Asim Bilen, Viraj A. Master, Dattatraya Patil, Michelle I. Higgins, Haydn T. Kissick, Kenneth Ogan
Publikováno v:
Journal of the American College of Surgeons. 231:S339
Autor:
Mehmet Asim Bilen, Bradley C. Carthon, J.W. Shelton, Adeboye O. Osunkoya, A. Jani, Karen M. Xu, Omer Kucuk, Mehrdad Alemozaffar, Christopher P. Filson, Pretesh Patel, Yingzi Liu, Theresa W. Gillespie, Ken Ogan
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 105:E315
Autor:
Caroline S. Jansen, Viraj A. Master, Mehmet Asim Bilen, Haydn T. Kissick, Jennifer W Carlisle, Nataliya Prokhnevska, Adriana Moon Reyes
Publikováno v:
Cancer Research. 79:2700-2700
Background: Tumor infiltrating immune cells have a clear prognostic benefit in many tumor types. Immune variables have independently improved prognostication in various cancer types, with tumor-infiltrating lymphocytes (TILs) more accurately predicti
Autor:
Louis L. Pisters, Deborah A. Kuban, Ana Aparicio, Dan Leibovici, Shi-Ming Tu, Marcy M. Johnson, Ferhat Evliyaoglu, Charles C. Guo, Mehmet Asim Bilen, Adriana Lopez
Publikováno v:
Cancer. 115:2872-2880
BACKGROUND: Ductal or endometrioid adenocarcinoma of the prostate may be a subtype of prostate cancer that is amenable to aggressive local therapeutic strategies. The authors of this report investigated the clinical outcome of patients who had prosta
Autor:
Mehmet Asim Bilen, Raghu Vikram, Shi-Ming Tu, Xuemei Wang, Paul G. Corn, Bradley J. Atkinson, Hsiang-Chun Chen, Diana H. Cauley, Diana Kaya, Jeri Kim
Publikováno v:
Journal of Clinical Oncology. 34:e16513-e16513
e16513Background: Cabazitaxel (CBZ) is a novel taxane approved after docetaxel in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). Though myeloid growth factors are comm...
Publikováno v:
Clinical breast cancer. 12(3)
Phyllodes tumors are rare fibroepithelial neoplasms of the breast; classified as benign, borderline, or malignant based on the mitotic activity, cellular atypia, and stromal overgrowth. Wide surgical excision is the treatment of choice. The most comm